55 results
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
surgery is unsuccessful in achieving treatment goals. Approximately 50% of patients with acromegaly prove to be candidates for pharmacotherapy
8-K
EX-99.1
CRNX
Crinetics Pharmaceuticals Inc
8 Jan 24
Regulation FD Disclosure
8:03am
~33,000 Patients Diagnosed with Carcinoid Syndrome (US) Facial flushing in a patient with carcinoid syndrome NETs Treatment Goals 1. Reduce frequency …
CRN04894: Second Clinical Asset In Late-Stage Development Skillfully Crafted to Help Patients Reach Their Treatment Goals Stress Hypothalamus Lead
8-K
EX-99.2
bn2h7a27h r5z
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-99.1
kfr6nok
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.1
75x2jua
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
8-K
EX-99.1
ee6p7byyh0lq9vs m7f
25 May 22
Regulation FD Disclosure
7:02am